Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.

JCO Clin Cancer Inform · 2023 · PMC10281428 · PMID 37075255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

For example, in the IPS cohort, there was a nonsignificant trend toward improved PFS with the weekly dose-dense carboplatin-paclitaxel compared with the standard arm (median PFS, arm 1: 21.5 months; arm 2: 23.5 months; and arm 3: 29.3 months), as well as improved OS (median OS, arm 1: 65.6 months; arm 2: 61.0 months; arm 3: 69.2 months).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.